Skip to main content

Table 2 Subgroup analysis: baseline demographics of patients with idiopathic pulmonary fibrosis before and after propensity score matching – all intensive care unit respiratory hospitalizations

From: Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications

  Before propensity score matching After propensity score matching
No Rx (N = 2039) Pirfenidone/Nintedanib (N = 274) Std. Diff No Rx (N = 274) Pirfenidone/Nintedanib (N = 274) Std. Diff
Age group
45–64 287 (14.1%) 39 (14.2%) 0.006 35 (12.8%) 39 (14.2%) 0.043
65–74 589 (28.9%) 111 (40.5%) 0.245 116 (42.3%) 111 (40.5%) − 0.037
75 +  1163 (57.0%) 124 (45.3%) − 0.238 123 (44.9%) 124 (45.3%) 0.007
Gender
Female 905 (44.4%) 78 (28.5%) − 0.336 85 (31.0%) 78 (28.5%) − 0.056
Male 1132 (55.6%) 196 (71.5%) 0.336 189 (69.0%) 196 (71.5%) 0.056
Race
White 1304 (64.0%) 179 (65.3%) 0.027 175 (63.9%) 179 (65.3%) 0.031
Black 168 (8.2%) 11 (4.0%) − 0.177 13 (4.7%) 11 (4.0%) − 0.036
Hispanic 218 (10.7%) 31 (11.3%) 0.020 27 (9.9%) 31 (11.3%) 0.047
Other 349 (17.1%) 53 (19.3%) 0.060 59 (21.5%) 53 (19.3%) − 0.054
Census region
Midwest 564 (27.7%) 71 (25.9%) − 0.040 65 (23.7%) 71 (25.9%) 0.051
Northeast 286 (14.0%) 31 (11.3%) − 0.082 38 (13.9%) 31 (11.3%) − 0.077
South 1008 (49.4%) 143 (52.2%) 0.056 142 (51.8%) 143 (52.2%) 0.007
West 181 (8.9%) 29 (10.6%) 0.057 29 (10.6%) 29 (10.6%) 0.000
Baseline comorbidities
Cardiac Arrhythmia 892 (43.7%) 108 (39.4%) − 0.087 112 (40.9%) 108 (39.4%) − 0.030
Congestive Heart Failure 845 (41.4%) 87 (31.8%) − 0.201 97 (35.4%) 87 (31.8%) − 0.077
Other Chronic Pulmonary Conditions 1568 (76.9%) 180 (65.7%) − 0.250 185 (67.5%) 180 (65.7%) − 0.039
Depression 407 (20.0%) 51 (18.6%) − 0.035 42 (15.3%) 51 (18.6%) 0.087
Diabetes 819 (40.2%) 104 (38.0%) − 0.044 109 (39.8%) 104 (38.0%) − 0.037
Hypertension 1600 (78.5%) 194 (70.8%) − 0.176 200 (73.0%) 194 (70.8%) − 0.049
Pulmonary Circulation Disorder 553 (27.1%) 86 (31.4%) 0.093 81 (29.6%) 86 (31.4%) 0.040
Renal Failure 486 (23.8%) 52 (19.0%) − 0.118 47 (17.2%) 52 (19.0%) 0.047
Solid Tumor without Metastasis 302 (14.8%) 40 (14.6%) − 0.006 38 (13.9%) 40 (14.6%) 0.021
Valvular Disease 551 (27.0%) 58 (21.2%) − 0.135 59 (21.5%) 58 (21.2%) − 0.009
Elixhauser comorbidity index
Mean (SD) 5.9 (3.3) 5.2 (2.9) − 0.258 5.1 (3.2) 5.2 (2.9) 0.004
Median 6.0 5.0 −  5.0 5.0 − 
Q1, Q3 3.0, 8.0 3.0, 7.0 −  3.0, 7.0 3.0, 7.0 − 
N hospitalizations in baseline
0 1132 (55.5%) 181 (66.1%) 0.217 178 (65.0%) 181 (66.1%) 0.023
1 535 (26.2%) 67 (24.5%) − 0.042 70 (25.5%) 67 (24.5%) − 0.025
2 +  372 (18.2%) 26 (9.5%) − 0.255 26 (9.5%) 26 (9.5%) 0.000
Year of hospitalization
2015 448 (22.0%) 30 (10.9%) − 0.301 30 (10.9%) 30 (10.9%) 0.000
2016 498 (24.4%) 69 (25.2%) 0.019 72 (26.3%) 69 (25.2%) − 0.025
2017 532 (26.1%) 84 (30.7%) 0.101 83 (30.3%) 84 (30.7%) 0.008
2018 561 (27.5%) 91 (33.2%) 0.124 89 (32.5%) 91 (33.2%) 0.016
Reason for admission
Diseases of respiratory system 1352 (66.3%) 136 (49.6%) − 0.342 136 (49.6%) 136 (49.6%) 0.000
Diseases affecting the interstitium 523 (25.6%) 132 (48.2%) 0.479 134 (48.9%) 132 (48.2%) − 0.015
All other reasons 164 (8.0%) 6 (2.2%) − 0.268 4 (1.5%) 6 (2.2%) 0.055
Pulmonologist visit 1136 (55.7%) 225 (82.1%) 0.595 230 (83.9%) 225 (82.1%) − 0.049
Smoker 1066 (52.3%) 135 (49.3%) − 0.060 134 (48.9%) 135 (49.3%) 0.007
Steroid use 1145 (56.2%) 183 (66.8%) 0.219 188 (68.6%) 183 (66.8%) − 0.039
Oxygen use 1249 (61.3%) 228 (83.2%) 0.430 219 (79.9%) 228 (83.2%) − 0.027